Viyash Scientific Ltd. (VIYASH) — Tipsheet

Viyash's Italian pet-care bid jumps 28% to ₹188 cr

Tipsheet Editorial — Mon, 08 Jun 2026 12:46:06 GMT

The final price for BioForLife is ₹41 crore above the figure Viyash disclosed earlier this year. The deal remains small against the company's own scale.

What’s new

Viyash signed a binding agreement to acquire Italian pet-care distributor BioForLife for ₹188 crore.
The price is 28% higher than the ₹147 crore Viyash disclosed for the same target earlier this year.
BioForLife supplies products to over 80% of Italian veterinary clinics. Viyash plans to use the network to launch Alivira pipeline products.

Why it matters

The ₹41 crore price jump is the story. Viyash's prior disclosure set an expectation; the binding agreement exceeds it without explanation. The strategic logic is consistent with past guidance, but the gap between numbers will need clarity.

What we’re watching

Any clarification on why the binding price is ₹41 crore above the initial disclosure.
Post-close integration of Alivira products into BioForLife's Italian distribution network.
How Viyash's capital allocation is perceived after this internal-accruals deal.

The full read

Viyash Scientific's final bid for BioForLife Italia is ₹188 crore. That is 28% more than the ₹147 crore it told the market earlier. The gap is unexplained. The company will fund the deal from internal accruals and expects it to close in Q2 FY27. BioForLife's value is its reach: it supplies nutritional supplements, pharmaceuticals, and diagnostics to more than 80% of Italian veterinary clinics. Viyash plans to launch its Alivira products through that network. The strategic logic is straightforward. The price increase is not. The prior disclosure set a benchmark the final agreement has now cleared, and the difference of ₹41 crore demands a rationale beyond the shift from a preliminary to a binding figure. The deal is small, at just 1.7% of Viyash's market cap, but the price move is a governance question.

Primary source: BSE · NSE

Viyash buys Italian vet distributor for €17M

Tipsheet Editorial — Mon, 08 Jun 2026 12:41:54 GMT

The €16.975M cash deal adds a direct sales platform in Italy's companion animal market. It's a strategic, not a financial, move for the mid-cap.

What’s new

Viyash's Irish subsidiary Alivira is acquiring all shares of BioForLife Italia, a Milan-based distributor of vet products for companion animals.
The binding cash deal is worth €16.975M. BioForLife had ~€9M in sales in 2025.
Closing is expected in three months, pending notification under Italy's Golden Power laws.

Why it matters

The deal is a tidy fit but a small one. It gives Viyash an instant front-end in Italy, a market it has targeted in Europe. Financially, the impact is minimal: the price is about 1.3% of its market cap, and the target's revenue is roughly 2.3% of Viyash's consolidated top line.

What we’re watching

The Italian government's Golden Power review. Foreign acquisitions can face conditions.
Integration of BioForLife's sales team and customer base.
The revenue contribution from Italy once the deal closes.

The full read

Viyash Scientific is paying €16.975 million cash for BioForLife Italia, a Milan-based distributor of vet products for companion animals. The target had €9 million in sales last year. Through its Irish subsidiary Alivira, Viyash gets an instant sales platform in Italy. The binding agreement should close in three months, pending Golden Power review. For Viyash, this is market penetration. The price is just 1.3% of its market cap, and the target's revenue is a fraction of the parent's. It's a small deal. But it's a deliberate one: Viyash is building a direct European front-end in a high-margin segment, one acquisition at a time.

Primary source: BSE · NSE

Viyash Scientific posts record quarter, sets ₹800 cr EBITDA run-rate for FY27

Tipsheet Editorial — Fri, 22 May 2026 10:36:13 GMT

Q4 revenue hit ₹920 crore and EBITDA jumped 64% to ₹200 crore. Management now sees the full-year EBITDA run-rate approaching ₹800 crore.

What’s new

Q4 FY26 revenue rose 19% to ₹920 crore; EBITDA surged 64% to ₹200 crore.
Management says the full-year FY27 EBITDA run-rate is approaching ₹800 crore.
Company is evaluating selective inorganic opportunities to strengthen its platform.

Why it matters

The record quarter and an ₹800 crore run-rate indicate a step-change in profitability. Management’s confidence in hitting ₹1,000 crore EBITDA within two to three years hinges on scaling two specific bets: companion animal health and CDMO services. The mention of inorganic moves suggests acquisitions could be the accelerant.

What we’re watching

Execution on the companion animal health and CDMO expansion plans.
Any announced inorganic deals and their valuation.
Whether the FY27 EBITDA run-rate translates into full-year delivery.

The full read

Viyash Scientific delivered its best quarter ever in Q4 FY26. Revenue rose 19% to ₹920 crore, and EBITDA jumped 64% to ₹200 crore on stronger formulation sales and better gross margins. That performance has management pointing to a full-year FY27 EBITDA run-rate of ₹800 crore, with a reiterated goal of ₹1,000 crore within two to three years. The two growth bets backing that target are companion animal health and CDMO. The new variable is inorganic growth. Management said it is actively evaluating selective acquisitions to strengthen the platform. The transcript confirms the financial beat but the real update is the roadmap and the appetite for deals.

Primary source: BSE · NSE

Viyash Scientific targets ₹1,000 cr EBITDA in 2-3 years, pivots to companion animals

Tipsheet Editorial — Thu, 21 May 2026 08:15:07 GMT

Management's May concall reaffirms synergy-led margin expansion and sets an FY27 EBITDA run rate of ~₹800 crore.

What’s new

Management guided for FY27 EBITDA run rate approaching ₹800 crore.
₹1,000 crore EBITDA target set for 2-3 years out.
Strategic pivot toward companion animals and CDMO expansion.

Why it matters

The concall adds confidence that Viyash's post-merger margin trajectory is sustainable beyond the immediate surge. With a clear roadmap to ₹1,000 crore EBITDA, the company is signalling that FY27 is a stepping stone, not a peak.

What we’re watching

Execution on the companion animal strategy.
CDMO order book build-up.
Whether the ₹800 crore run rate is achieved in H1FY27 or needs the full year.

The full read

Viyash Scientific's May concall did more than confirm record Q4 numbers — it laid out a strategic roadmap that stretches well beyond the current fiscal. Management pegged the FY27 EBITDA run rate at nearly ₹800 crore, with a ₹1,000 crore target within 2-3 years, built on a deliberate shift toward companion animals and an expanding CDMO franchise. The post-merger synergy outperformance cited suggests margins have room to grow even as the revenue mix evolves. While the numbers were pre-disclosed, the qualitative detail on strategic intent gives a fresher lens to value a mid-cap pharma company shaping its own narrative. The open question is whether operational momentum sustains through the transition — but the call offered enough specificity to make the bull case credible.

Primary source: BSE · NSE